% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • marinolman11 marinolman11 Oct 16, 2013 2:31 PM Flag

    Anyone read this and care to speak to it?

    Exelixis’ cabozantinib faces tolerability issues in achieving efficacious prostate cancer dose –

    Biopharm insight website

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You stated where you got your info, however, what are they basing their statement on. If it's a rehash of old information, it's simply misleading readers but many times someone posts that there is a new article written by someone except that it is republication of old information.

    • Yes: buy EXEL It is going much higher. Read below:

      Yoffe: There is a bear case on COMET-1 Phase III trial that states that the trial may miss its primary endpoint for being underpowered. What is your impression?
      Dr. Schmidt: Based upon the trial design of COMET-1 being similar to other recent studies in mCRPC (Zytiga, Xtandi, and Xofigo) and the fact that these studies were halted at the interim analysis due to highly statistically significant data, I believe COMET-1 is overpowered to demonstrate any meaningful efficacy for cabozantinib.
      Yoffe: Do you believe that the strong efficacy of Xtandi and Zytiga may increase Cometriq's hurdle to achieve significant survival benefit in mCRPC?
      Dr. Schmidt: COMET-1 is testing cabo after Ztyiga and/or Xtandi. Once a patient fails one of these androgen-based drugs, they tend to respond poorly to anything else in the cascade. Hence I do not think post-trial exposure to Zytiga or Xtandi will confound the results.
      Yoffe: What is Cometriq's market potential in mCRPC?
      Dr. Schmidt: We think a later-line drug in prostate cancer could deliver sales of ~$500MM in the U.S.
      Yoffe: What is your opinion on the company's ongoing commercial launch of Cometriq in the U.S.?
      Dr. Schmidt: Cometriq has surpassed all expectations for early sales trends, likely due to off-label utilization. Although the commercial opportunity for Cometriq will likely be modest pending success from at least one of the ongoing trials, we interpret the off-label interest as a favorable signal.

      Yoffe: Do you believe that the company's other programs will result in commercial products?
      Dr. Schmidt: We expect Roche's (RHHBY.OB)/Exelixis's MEK inhibitor (GDC-0973) to succeed in an ongoing Phase III trial in melanoma in combination with Zelboraf. EXEL is entitled to 30-50% of U.S. profits on this candidate.
      Yoffe: How far can Exelixis go with the current funding?
      Dr. Schmidt: We believe the company is financed into 2015 and through the key COMET-1 and COMET-2 readouts

      Sentiment: Buy

6.4564+0.3364(+5.50%)10:02 AMEDT